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Drug therapies for advanced breast cancer in hormone-receptor-positive disease include both hormonal and chemotherapies.
Current UK practice is to minimise toxicity by using sequential hormonal agents for as long as clinically appropriate. A Markov model
was developed to investigate the cost effectiveness of different sequences of therapies, particularly exploring the effects of adding an
additional hormonal agent, fulvestrant, to the treatment pathway. A systematic review was undertaken and a panel of seven UK
oncologists validated assumptions used for treatment efficacy, treatment pathways and resources used. Fulvestrant was found to be a
cost-effective treatment option when added to the treatment sequence as a second- or third-line hormonal therapy for advanced
disease. For a cohort of 1000 patients, fulvestrant as a second-line hormone therapy provided an additional 47 life years and 41
quality-adjusted life years (QALYs), at an additional cost of d301359. This equated to d6500 per life years gained and d7500 per
QALY. When used as a third-line option, the fulvestrant arm was dominant providing an increase in health benefit of 27 QALYs for
the whole cohort, at a mean overall cost reduction of d430 per patient. Sensitivity analyses showed these results to be robust,
demonstrating that fulvestrant is an economically viable additional endocrine option in the United Kingdom for the treatment of
hormone responsive advanced breast cancer.
British Journal of Cancer (2008) 99, 1984–1990. doi:10.1038/sj.bjc.6604790 www.bjcancer.com
Published online 18 November 2008
& 2008 Cancer Research UK
Keywords: cost effectiveness; advanced breast cancer; Faslodex; fulvestrant; hormone receptor positive
                                                 
Breast cancer is the most common form of malignancy among
women in western Europe, with one in every eight women
developing the disease at some point in their lives (American
Cancer society, 2006). Despite recent improvements in survival
through increased awareness, screening and the wider use of
hormonal therapy and adjuvant chemotherapy, advanced breast
cancer remains a common clinical problem in the United
Kingdom, accounting for 17% of cancer-related deaths in women
(Cancer Research UK, 2005).
Hormonal therapies applicable for women whose disease is
hormone-receptor positive (HRþ) have been introduced. Among
these have been the third-generation aromatase inhibitors (AIs),
anastrazole, letrozole and exemestane, which are increasingly
being used in the adjuvant setting. However, many postmenopau-
sal women relapse after adjuvant hormonal therapy, with a median
survival of 17–22 months post-relapse (Scottish Intercollegiate
Guidelines Network (SIGN), 2005), demonstrating a need for more
effective therapies in this patient population (Robertson et al,
2003).
Fulvestrant (Faslodex
s) is an oestrogen receptor antagonist
with a novel mode of action, which is administered by monthly
intramuscular injection. Fulvestrant is licensed in the United
Kingdom for the treatment of postmenopausal women with
oestrogen-receptor positive, metastatic breast cancer whose
disease has progressed or relapsed on or after previous anti-
oestrogen therapy. Several clinical studies have confirmed that
fulvestrant is at least as effective as AIs in the treatment of
advanced breast cancer in patients with HRþ disease (Howell
et al, 2002, 2004, 2005; Osborne et al, 2002; Robertson et al, 2003;
Ingle et al, 2006). In addition, clinical evidence shows that the
addition of fulvestrant into a sequence of well-tolerated hormonal
therapies can be undertaken without a detrimental effect on
responses to subsequent treatments (Vergote et al, 2003; Howell
et al, 2005).
In the absence of international guidelines, common current
practice for the treatment of HRþ advanced breast cancer in
many countries, including the United Kingdom, consists of
sequential administration of hormonal therapies, prolonging the
use of endocrine therapy while the disease status allows before
switching to more toxic chemotherapies. This requires the
availability of a range of therapies with different modes of action,
so that tumours developing resistance to one agent are not cross-
resistant to another (Steger et al, 2005). For postmenopausal
women with HRþ breast cancer previously treated with adjuvant
tamoxifen, this is often achieved by first using a non-steroidal AI
followed by a sequence consisting of a second AI, usually a
steroidal drug. However, given the practical difficulties associated
with conducting a study of this sort, there are currently no clinical
studies investigating the optimal sequencing of hormonal treat-
ments or of using fulvestrant as an additional step within a
sequence of hormonal treatments (Tobias, 2004; Laffaioli et al,
2005; Bertelli and Paridaens, 2006).
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sCost-effectiveness evidence is increasingly required by health-
care payers in the United Kingdom to support decisions regarding
the inclusion of new drugs on hospital formularies, as well as by
national bodies such as the National Institute for Health and
Clinical Excellence (NICE) and the Scottish Medicines Consortium.
This has provided the rationale to develop a robust health
economic model that brings together the best available evidence
for the efficacy and safety of different treatment options to
estimate relevant overall health outcomes and costs. This model
could then be used to investigate whether an additional endocrine
treatment step, such as fulvestrant, in a sequence of hormonal
treatments for advanced breast cancer is a cost-effective use of the
limited UK National Health Service (NHS) resources.
MATERIALS AND METHODS
Markov model structure
In the absence of prospective clinical and health economic data
based on a single clinical trial, a Markov cohort simulation model
was developed using Microsoft Excel to project longer term clinical
and economic consequences for the treatment of postmenopausal
women with HRþ advanced breast cancer. The model consists of
health states representing each separate line of therapy and death.
The model was set up to compare two cohorts of identical patients
receiving different treatment sequences of up to five treatments
including best supportive care (BSC). Best supportive care was
defined as palliative therapy while not on any active treatment and
is the package of care given when no active treatments are deemed
appropriate for a patient due to treatment toxicity, patient frailty
or expected lack of benefit given poor prognosis. Cohort A
included the option of fulvestrant as either a second or third
therapy in the sequence, whereas Cohort B did not include
fulvestrant (Figure 1). Seven UK clinicians (oncologists) were
interviewed to obtain information on the most common treatment
pathway and clinical and economic parameters which were not
available in the literature.
The Markov cycle length defines the unit of time used for
assessing the probability of transition between health states within
Markov models, and should be based on the natural history of the
disease (Briggs and Sculpher, 1998; Philips et al, 2006). In our
analysis, a Markov cycle length of 28 days was used. The clinicians
interviewed felt that a monthly cycle was the most robust option
given that most patients are seen in clinic at intervals that are
multiples of whole months (1, 2 or 3). In addition, the 1-month
treatment cycle was deemed the optimal length to reflect both
timing of measurement of disease progression and to maintain
adequate simplicity in the model structure.
At the end of each Markov cycle, patients could either remain on
their current line of treatment, experience disease progression and
move to another line of treatment or die. The probability of any of
these events occurring is dependent on treatment-specific median
time to progression (TTP) data and the probability of dying on
each treatment. Once patients had experienced a progressive event
they could move to any later health states to reflect actual clinical
practice. The health states and possible transitions of patients for
each cohort are shown in Figure 2.
Each cohort consisted of 1000 postmenopausal women with
HRþ advanced breast cancer, assumed to have previously
received adjuvant tamoxifen. For computational reasons after 10
years of simulation, all patients in the model were assumed to have
died and this was considered to be a reasonable assumption by the
clinicians interviewed.
Clinical data
A systematic review of randomised controlled trials and other
experimental studies published between 1998 and 2006 was
conducted to identify evidence on TTP for treatments in the
selected sequences. Data on the TTP and, where appropriate, the
results for a given treatment at a given line of therapy were pooled
using meta-analysis and standard statistical methods (DerSimo-
nian and Laird, 1986). A summary of the meta-analysis results
for hormonal treatments is presented in Table 1. Time to
progression data for chemotherapies were obtained from indivi-
dual studies that presented sufficient information (Blum et al,
1999; O’Shaughnessy et al, 2002) (Table 1).
Proportion dying at each treatment line
The proportions of patients dying at each treatment line were
estimated from the clinicians survey, as these data were not
available in the literature (Table 2).
Treatment skipping
The model allowed for the fact that, in clinical practice, not all
patients will receive all treatments in sequence. Estimates for
Cohort A: with
Cohort B: without
Cohort B: with
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Fulvestrant used as a second-line hormonal therapy for advanced breast cancer
Fulvestrant used as a third-line hormonal therapy for advanced breast cancer
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Figure 1 Treatment sequences for Cohort A (with fulvestrant) vs Cohort B (without fulvestrant).
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streatment skipping were derived from the clinician survey, as these
data were not available in the literature:
(1) For Cohort B, it was assumed that: 27% would go straight to
chemotherapy and 9% straight to BSC from first-line
hormonal therapy (AI); 42% would go straight to BSC from
second-line hormonal therapy.
(2) When fulvestrant is included in the sequence (Cohort A), it
was assumed that: 27% would go straight to chemotherapy and
9% would go straight to BSC from first-line hormonal therapy;
27% would go straight to BSC from second-line hormonal
therapy; 15% would go straight to BSC from third-line
hormonal therapy.
Costs
The economic evaluation was carried out from the UK NHS
perspective and therefore includes only direct medical costs. The
direct costs included drug acquisition, health-care resource use
associated with treatment administration and monitoring the
underlying disease, BSC requirements and treatment of serious
adverse events requiring hospitalisation or adverse events with
incidence of at least 5%.
The unit drug acquisition costs for hormonal and chemothera-
pies was derived from British National Formulary (British National
Formulary, 2006) (Table 3).
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Figure 2 Overview of the sequencing model patient.
Table 1 Median TTP (pooled) for hormonal and chemotherapy treatment by line of treatment
Treatment Line of treatment Median TTP (months) 95% CI
Anastrozole (Nabholtz et al, 2003; Rose et al, 2003) First 8.50 7.38, 9.62
Exemestane (Lonning et al, 2001; Thurlimann et al, 2004; Gradishar et al, 2007) First 8.90 7.20, 10.60
Letrozole (Buzdar et al, 2001; Tominaga et al, 2002; Rose et al, 2003) First 9.40 6.48, 12.32
Exemestane (Lonning et al, 2001; Thurlimann et al, 2004; Gradishar et al, 2007) Second 4.16 3.47, 4.86
Fulvestrant (Robertson et al, 2003; Ingle et al, 2006; Gradishar et al, 2007) Second 4.50 2.66, 6.34
Fulvestrant (Gradishar et al, 2007) Third 3.68 3.45, 5.23
Exemestane (Lonning et al, 2001; Gradishar et al, 2007) Third 3.72 3.09, 4.35
Docetaxel (O’Shaughnessy et al, 2002) First /second /third 4.2 3.36, 5.04
Capecitabine (Blum et al, 1999, 2001) First /second /third 3.1 2.48, 3.72
Table 2 Proportion of patients who progress to death at each treatment
line
Proportion of patients dying
Treatment line
Cohort A
(with fulvestrant)
Cohort B
(without fulvestrant)
1 0.19 0.19
2 0.23 0.23
3 0.28 0.28
4 0.35 0.35
5 0.5 1.0
6 1.0 —
Source: UK clinicians survey.
Table 3 Costs of drug treatments in the sequencing model for the
United Kingdom
Dose
Days each
unit
prescribed
Costs
per
cycle
Fulvestrant 250mg every 4 weeks 28 d348.27
NSAI
(anastrazole)
a
1mg daily 28 d68.56
Exemestane 25mg daily 28 d82.88
Docetaxel 100mg/1.73m
2 21 d1,254.00
Capecitabine Dose 1250mg/m
2 twice
daily for 14 days, then 7 days
interval
21 d296.24
aThe cost is similar to letrozole and is assumed that clinical behaviour is most likely to
be independent of non-steroidal AI used. Source: British National Formulary, 2006
(British National Formulary, 2006).
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estimates (e.g., outpatient visits, GP/nurse visits and nurse home
visits) were derived from the clinician survey.
The estimated resource use for BSC (health professional
consultations, inpatient and hospice stays, radiotherapy and
palliative medicine) was also taken from the clinician survey. Costs
were calculated by multiplying resource use per patient with the
unit cost of resources. All unit costs for resources were taken from
nationally published sources, and reported in pounds (d) at 2005
prices (Curtis and Netten, 2005; British National Formulary, 2006).
Utilities
The specific outcome measures used to evaluate effectiveness in
the economic model were life years (LY) and quality-adjusted life
years (QALY) gained. The estimation of QALYs gained comparing
cohort B with A requires the derivation of a quality of life (utility)
weighting on a scale of 0–1 for the different treatment lines, taking
into account the impact of toxicities for each treatment in the
sequence.
Appropriate utility values were not available from the literature;
therefore, the clinicians in the survey were asked to estimate on a
0–100 point visual analogue scale (VAS) the quality of life
associated with each line of treatment in the sequence. Their
recorded values were then rescaled to 0–1. The resulting mean
utilities are presented in Table 4.
Base case analysis
The cost-effectiveness output was calculated using the incremental
cost-effectiveness ratio (ICER), which divides the difference in
total health-care costs by the difference in benefits (LYs or QALYs
gained) for the two cohorts of patients. The ICERs of below d30000
per QALY gained are generally considered to be representative of a
cost-effective use of UK NHS resources (Rawlins and Culyer, 2004).
In economic evaluations, future costs and benefits are
discounted to reflect a personal and societal time preference to
delay costs but to have health benefits in the current time period.
On the basis of current NICE guidance, an annual discount rate of
3.5% for both costs and benefits (QALY or life years gained (LYG))
was used in the base case economic analysis (National Institute for
Clinical Excellence (NICE), 2006).
Sensitivity and scenario analysis
For the base case treatment sequence comparison, probabilistic
sensitivity analysis (PSA) involving 1000 random simulations of
the median TTP was performed to quantify the uncertainty around
TTP estimates used in the model. The PSA is a technique for
testing the robustness of the results from the model by varying
multiple parameters simultaneously to see if the cost-effectiveness
conclusions are affected. This assessed the level of uncertainty in
the cost-effectiveness result and utilised 95% confidence intervals
around the TTPs. The results from the PSA were plotted onto a
cost-effectiveness plane and a cost-effectiveness acceptability curve
(CEAC). The CEAC shows the probability that adding fulvestrant
to the treatment sequence is cost effective for a given threshold
willingness to pay (WTP) ceiling ratio, that is, the assumed
maximum amount a decision maker would be willing to pay for an
additional unit of effect (QALY or LYG).
The following one-way sensitivity analyses were performed to
further explore the robustness of the model assumptions:
(a) Discount rate for costs and benefits were varied between 0 and
6%.
(b) The same efficacy for fulvestrant and exemestane at second
and third line was assumed.
(c) To reflect the multiple potential chemotherapy options in
advanced breast cancer, the use of different chemotherapies in
the sequence was tested. First, the CMF regimen (cyclophos-
phamide, methotrexate and fluorouracil) was used instead
of capecitabine as a second-line chemotherapy. Second, doxo-
rubicin was used instead of docetaxel as the first-line
chemotherapy.
(d) To reflect uncertainty around chemotherapy effectiveness and
use in later lines of therapy an increased median TTP of 6.5
(Chan et al, 1999) months and an average number of cycles of
4 was assumed for docetaxel.
(e) To test the robustness around the number of patients avoiding
chemotherapy, a scenario was tested where the number of
patients going on to receive docetaxel was the same in both
cohorts.
RESULTS
Fulvestrant as a second-line hormonal therapy
Cohort A consisted of 1000 postmenopausal women with HRþ
advanced breast cancer receiving fulvestrant as a second-line
hormonal therapy for advanced disease. The model estimated the
total numbers of patients in cohort A who would begin treatment
with the following drugs in sequence as: anastrozole/letrozole
(1000), fulvestrant (518), exemestane (291), docetaxel (397),
capecitabine (258) and BSC (341). For cohort B, without the
addition of fulvestrant, the numbers of patients estimated to be
receiving treatment at each line in the sequence were as follows:
anastrozole (1000), exemestane (518), docetaxel (450), capecita-
bine (324) and BSC (451). These estimates are based on the
probability of progression, estimates used for treatment skipping
and proportion of patients expected to die at each treatment line.
Hence, in cohort A, 655 chemotherapy regimens were delivered
compared with 774 in cohort B. This reduction in the number of
patients who received chemotherapy was influenced by the results
of the physician survey, which suggested some patients would die
while on therapy and others would skip their next therapy. This
assumption was varied in a sensitivity analysis.
In the base case analysis, the addition of fulvestrant to the
treatment sequence produced an estimated health gain per 1000
women of 56 LYs and 41 QALYs at an additional net cost of
d301359. Per patient this equates to an estimated survival gain of
0.6 months for an additional net cost of just over d300 (Table 5).
The resulting ICER was d6500 per LYG and d7300 per QALY. The
majority of costs were incurred while on final treatments, while the
majority of benefits (QALYs/LYG) were generated through the
earlier treatments.
Fulvestrant as a third-line therapy after two AIs
An alternative scenario positioning fulvestrant as third-line
hormonal therapy in cohort A, with exemestane shifting from
third- to second-line hormonal therapy, resulted in the sequence
with fulvestrant ‘dominating’ the sequence without. The sequence
containing fulvestrant both increased health benefits (LYGs and
Table 4 Utility values for each treatment in the sequence
Cohort A (with fulvestrant) Cohort B (without fulvestrant)
1 0.81 0.81
2 0.73 0.73
3 0.53 0.42
4 0.42 0.42
5 0.35 —
BSC 0.19 0.19
Death 0.00 0.00
Source: UK clinician survey.
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estimated cost saving of d430 per patient. The difference between
this and the base case result occurs because fewer patients actually
receive fulvestrant in this scenario. This results in a lower total
benefit gain, but also a lower total cost for scenario A, than when
fulvestrant is used as second-line therapy option. Ultimately,
however, the addition of fulvestrant in both scenarios is
cost effective as we see increased levels for benefits of Cohort A
over Cohort B, as fewer patients proceed to receiving chemother-
apy, which is usually more toxic and expensive than hormonal
therapy.
Sensitivity analyses
The PSA suggested that the addition of fulvestrant into the
sequence as either a second- or third-line therapy has a greater
than 60 or 70% probability of being viewed as a cost-effective
treatment, respectively, given a WTP for a QALY of d30000. The
full cost-effectiveness acceptability curves for the base case
analyses have been included as Supplementary Information
(Figures 3–4).
Varying the discount rates for costs and benefits between 0
and 6% resulted in a range of incremental cost per QALY
gained estimates of d6267–d7813 per QALY gained. The ICER
range using LYG as the outcome measure followed a similar
pattern.
On the basis of the results of the EFECT study (Gradishar et al,
2007), one-way sensitivity analysis assuming the same efficacy
(TTP) for fulvestrant and exemestane as a third-line therapy
resulted in Cohort A dominating Cohort B, again attaining a
greater health gain with a reduction in total costs of d425 per
patient. This was very similar to the results for the base case.
For a scenario of CMF as the second chemotherapy choice after
second line use of fulvestrant, the ICER was estimated to be
d13673 per QALY gained compared to the cohort B sequence, and
‘dominant’ if fulvestrant was included as third-line hormonal
therapy for advanced disease use in the sequence. Where
Doxorubicin was used as the first-line chemotherapy choice, the
analysis reported an ICER of around d16000 per QALY where
fulvestrant was used as a second-line option, and Cohort A
remained ‘dominant’ where fulvestrant was used as the third-line
hormonal option.
For sensitivity scenario D, where docetaxel is assumed to have
increased efficacy and is given for a reduced number of cycles, the
ICERs for second-line use of fulvestrant were d15773 and d14423
per LYG and QALY, respectively. Where fulvestrant is added as a
third-line therapy, that sequence continues to dominate.
For the final sensitivity analysis where the number of patients
receiving chemotherapy on both arms is equalised, this scenario
results in cost per QALY’s of d24000 and d19000, respectively, as
fulvestrant is added as a second- and third-line hormonal option.
As might be expected, these results are higher than the base case.
DISCUSSION
Several clinical studies have shown similar efficacy for fulvestrant
compared with AIs together with a consistently good tolerability
profile (Howell et al, 2002, 2004, 2005; Osborne et al, 2002;
Robertson et al, 2003; Ingle et al, 2006; Gradishar et al, 2007; Chia
et al, 2008). However, no clinical studies have been conducted that
address the issues of effectiveness and cost effectiveness of
different treatment sequencing options for women with HRþ
advanced breast cancer – a very important question, given
standard clinical practice for treating advanced breast cancer. To
address this question within a UK context, we constructed a
Markov cohort sequencing model to provide the analytical
framework to synthesise the available efficacy, safety and cost
data for sequences of therapies.
The effects of adding fulvestrant as second- or third-line
hormonal therapy for advanced disease were considered. The
key results suggested that the option to prescribe an additional
hormonal agent was a cost-effective strategy for either of these
scenarios when compared with a strategy where prescribing
fulvestrant was not an option.
Use of fulvestrant as a third-line hormonal therapy for advanced
disease was a highly cost-effective option, as it dominated the
comparator option with lower costs and increased benefits. The
additional cost effectiveness was mainly derived from the lower
total drug acquisition costs when fulvestrant is used as third-line
hormonal therapy for advanced disease. This is because fewer
patients per cohort would receive the treatment in this setting as
compared with second line. However, it should be noted that this
model was not designed to examine where to place fulvestrant in
the treatment sequence, which should remain a patient-specific
clinical question. Rather the analysis suggests that the addition of
fulvestrant to the endocrine treatment sequence for appropriate
patients is cost effective whether positioned as a second- or third-
line endocrine therapy.
In terms of specific benefits, the model estimates that second-
line hormonal therapy with fulvestrant will result in fewer patients
Table 5 Key results for second and third line use of fulvestrant
Second line use of fulvestrant Third line use of fulvestrant
Cohort A
(with
fulvestrant)
Cohort B
(without
fulvestrant) Difference ICER*
Cohort A
(with
fulvestrant)
Cohort B
(without
fulvestrant) Difference ICER
NSAI (anastrazole/ letrozole) d1233 d1233 d0 d1260 d1260 d0
Fulvestrant d2037 d2037 d755 d755 d0
Exemestane d472 d725  d253 d1296  d400
Docetaxel d4151 d4572  d421 d4345 d4745  d400
Capecitabine d1120 d1302  d182 d1198 d1382  d182
BSC d2713 d3593  d880 d2802 d3857  d1055
Cost per patient d11725 d11424 d301 d11055 d11424  d370
Mean survival (months) 22.3 21.7 0.56 22.34 21.87 0.468
Life years per patient 1.86 1.81 0.05 1.86 1.82 0.04
QALYs per patient 1.18 1.14 0.04 1.178 1.142 0.036
Incremental cost per LYG — d6500 — Cohort A dominant
Incremental cost per QALY gained — d7300 — Cohort A dominant
LYG¼life years gained; QALYs¼quality-adjusted life years; ICER¼incremental cost effectiveness ratio.
*ICER values may not be directly derived from the figures presented in the table due to rounding errors. ICER values presented the nearest hundred pounds.
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with cost savings associated with delayed or reduced use of
chemotherapy as well as patient benefits. This is because women
with advanced breast cancer spend a greater proportion of time on
hormonal treatments, which maintain a higher quality of life
than chemotherapies. In addition, there is evidence indicating
that some patients have a preference for a monthly injection
compared with daily tablets, the formulation of many other
hormonal agents (Fallowfield et al, 2006). Given an implicit
threshold for cost-effective use of NHS resources in the United
Kingdom of d20–d30000, these estimates fall well within the
threshold.
The PSA showed that the addition of fulvestrant into the
treatment sequence had a relatively high probability of being a
cost-effective treatment option despite the multiple data sources
used for input parameters. Multiple one-way sensitivity analyses
were also conducted on the results to test major assumptions, and
all these continued to suggest cost-effective results, confirming the
robustness of the model.
Overall, the results suggest that the option of an additional
hormonal agent, such as fulvestrant, in the sequence of therapies
for advanced breast cancer is a cost-effective treatment strategy.
The decision as to when to use fulvestrant in the sequence and in
which patients must remain a clinical one; however, it has been
shown that when used in appropriate patients, fulvestrant is a cost-
effective strategy.
There are a number of possible limitations with the analysis. It
may be suggested that a BSC treatment in place of the additional
hormonal agent might also be cost effective, as it may also delay
and reduce the amount of expensive chemotherapy consumed. At
present, there are no data available to fully evaluate this scenario in
the model framework given that it is not commensurate with
clinical practice. However, it may be postulated that this scenario
would not result in the additional QALYs gained that the present
results suggest for the fulvestrant arm.
Second, the lack of direct clinical trial data comparing the
addition of fulvestrant to a sequence of treatments for advanced
breast cancer without fulvestrant may be considered a data
limitation. However, the sequencing model is a pragmatic
alternative to a complex problem that may represent clinical
realities better than would be possible with a single trial. A specific
treatment sequence was adopted for the UK context, but the model
is fully flexible to compare other treatment sequences. It also
provides a framework for synthesising and making best use of a
range of data inputs using formal and robust statistical methods,
such as meta-analysis, supported by expert clinical opinion, to
inform a specific health-care decision problem. The limitations
still remain in this particular analyses, for example the chemother-
apy options in the model are illustrative rather than comprehen-
sive. However, as sensitivity analysis showed, the specific choice of
chemotherapy regimen may not be expected to have a large impact
on the cost-effectiveness results. In addition, utility estimates were
drawn from clinician opinion on a VAS, rather than from patients.
Nevertheless, the estimates are comparable to those reported for
advanced breast cancer patients on chemotherapy (Hutton et al,
1996).
While several chemotherapy options were examined in the base-
case and sensitivity analyses, it should be noted that there are
many other options, for example, other taxanes could be used
instead of docetaxel. However, the choices in the reported analyses
represent some of the extremes of acquisition cost, so assuming a
similar level of efficacy for these agents, these data suggest that
whichever chemotherapy is used the conclusion of this analysis
will hold.
Finally, although this analysis attempts to cover the most
common sequences used in the treatment of HRþ advanced
breast cancer, the complexity of the treatment and the limitations
of the model mean it is inevitable that not all possible sequences
will be covered. One such example is a situation where
patients initially receive a chemotherapy and are then given
hormonal therapy once the disease is ‘controlled’ or the maximum
number of cycles is reached. These additional sequences are
potentially important and should be considered areas for further
research.
However, in general, this model predicts that in clinical practice
approximately one-third of all HRþ advanced breast cancer
patients may be eligible for fulvestrant in the United Kingdom. For
these patients, the analyses suggest that the addition of fulvestrant
to the treatment sequence can be considered cost effective and that
fulvestrant is an economically viable additional endocrine therapy
step for the UK NHS in the treatment of postmenopausal women
with hormone-responsive advanced breast cancer.
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